Skip to content
Clinical Trials – home
CroatiaBack to Croatia

Clinical trials in Ivanic-Grad

259 clinical trials in Ivanic-Grad, Croatia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Ivanic-Grad at a glance
259
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

259 trials in Ivanic-Grad

Open in trial search

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:LY4268989 adipic acid
  • Sponsor:Eli Lilly & Co.

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim Espana S.A.

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

BI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:BI 3000202
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Ivanic-Grad

What the registry says about research in the country

01 Dermatology Research

Innovative clinical trials focusing on atopic dermatitis are evaluating new therapeutic approaches for both adolescents and adults with moderate to severe conditions. The research aims to assess novel treatment combinations and their effectiveness in managing eczema symptoms.

  • Moderate to Severe Atopic Dermatitis
  • Combination Therapy Studies
  • Systemic Treatment Options

Research includes evaluation of topical corticosteroid combinations and long-term treatment outcomes.

02 Inflammatory Skin Conditions

Studies are underway examining treatments for hidradenitis suppurativa, particularly focusing on patients who haven't responded well to conventional therapies. This research explores alternative treatment options for moderate to severe cases.

  • Treatment-Resistant Cases
  • Advanced Therapeutic Options
  • Anti-TNF Therapy Alternatives

The research specifically targets patients who have shown resistance to traditional treatments.

03 Advanced Therapeutics

Cutting-edge research investigating rezpegaldesleukin and other novel biologics for treating moderate-to-severe skin conditions. These trials are specifically designed for biologic-naive patients seeking new treatment options.

  • Biological Therapy Assessment
  • Dose Optimization Studies
  • Clinical Efficacy Evaluation

Focus includes measuring treatment effectiveness through standardized assessment tools.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.